Press Release

<< Back
May 14, 2014 at 7:00 AM EDT

Verastem to Present at Upcoming Investor Conferences

CAMBRIDGE, Mass.--(BUSINESS WIRE)--May 14, 2014-- Verastem, Inc., (NASDAQ:VSTM) focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells, announced that members of the management team will be presenting at upcoming investor conferences. The presentation details are as follows:

  • UBS Global Healthcare Conference on Monday, May 19, 2014, at 3:30 p.m. ET at the Sheraton New York Hotel in New York City
  • Jefferies Global Healthcare Conference on Wednesday, June 4, 2014 at 2:00 p.m. ET in New York City

Webcasts of the conference presentations can be accessed by visiting the investors section of the Company’s website at Replays of the webcasts will be archived on the Verastem website for 90 days following the presentation date.

About Verastem, Inc.

Verastem, Inc. (NASDAQ:VSTM) is discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells. Cancer stem cells are an underlying cause of tumor recurrence and metastasis. Verastem is developing small molecule inhibitors of signaling pathways that are critical to cancer stem cell survival and proliferation: FAK, PI3K/mTOR and Wnt. For more information, please visit

Forward-looking statements:

Any statements in this press release about future expectations, plans and prospects for the Company constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by such forward-looking statements. The Company anticipates that subsequent events and developments will cause the Company’s views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so.

Source: Verastem, Inc.

Verastem, Inc.
Brian Sullivan, 617-252-9314

Investor Contact

John Doyle

VP Investor Relations & Finance

Joe Rayne

Argot Partners